Biocad goals go beyond putting Russian biotech on the map

29 November 2016
biosimilars_samples_large

Roman Ivanov, vice president of research and development (R&D) at Biocad, describes his company’s current transition as going from being a local biosimilar player in its native Russia, to a global mid-sized biopharmaceutical player, in an interview with The Pharma Letter's Guy Martin.

When he talks about the privately-held company’s already-approved monoclonal antibody (MAb) biosimilars, the impact they have had on drug access in emerging markets, as well as Biocad’s pipeline of around 40 of its own drug candidates and ambitions to target regulated markets, it is clear that the company could have a major impact internationally.

"Checkpoint inhibitors have made a revolution in terms of treatment of cancer, but the enormous cost of those drugs is prohibitive in emerging markets, but also for developed markets"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars